The number of Xarelto lawsuits continues to grow by leaps and bounds at both the federal and state level, according to court records. Approximately 100 Xarelto cases were filed between March 16 and April 17, 2015, and of those, 402 federal lawsuits are now pending in multidistrict litigation in the U.S. District Court, Eastern District of Louisiana. Dozens more were added on the state level as well, as the Philadelphia Court of Common Pleas reported on April 23 that at least 204 Xarelto lawsuits are now pending in Pennsylvania’s mass tort proceeding, an increase of 50 cases in the month of March alone. Childers, Schlueter & Smith is currently investigating and filing new Xarelto cases on a daily basis. Given all the serve uncontrolled bleeding risks called by Xarelto and the fact that Xarelto is still on the market, thousands more cases are expected in the months ahead. Xarelto Litigation The consolidated litigations in Pennsylvania and Louisiana were established to allow Xarelto lawsuits that make similar allegations to avoid duplication and move more efficiently through the court system. The allegations that the Xarelto lawsuits make include life-threatening events of internal bleeding and other complications due to the drug’s use. Patients harmed by Xarelto use may be eligible to be compensated for:
- Medical bills, present and future
- Lost wages
- Loss of earning capacity
- Pain and suffering
- Emotional anguish
- Loss of enjoyment of life
Xarelto History The U.S. Food and Drug Administration (FDA) approved Xarelto (rivaroxaban) in 2011 for use in reducing the risk of blood clots in patients undergoing knee and hip replacement surgery. Later that same year, approval was extended for reducing the risk of blood clots and stroke in patients with non-valvular atrial fibrillation. Xarelto’s manufacturers marketed the medication as a more convenient alternative to the popular warfarin, which requires frequent blood monitoring. But recent findings regarding dangerous side effects now question the safety of Xarelto’s one-size-fits-all approach, which does not require frequent follow-up. Some of these side effects include blood clots, fatal pulmonary embolism, and major bleeding events that have resulted in death.